Beau-Faller M - Search Results

1

Plasma DNA microsatellite panel as sensitive and tumor-specific marker in lung cancer patients.

Beau-Faller M, Gaub MP, Schneider A, Ducrocq X, Massard G, Gasser B, Chenard MP, Kessler R, Anker P, Stroun M, Weitzenblum E, Pauli G, Wihlm JM, Quoix E, Oudet P. Beau-Faller M, et al. Int J Cancer. 2003 Jun 20;105(3):361-70. doi: 10.1002/ijc.11079. Int J Cancer. 2003. PMID: 12704670

2

Association of genetic defects in primary resected lung adenocarcinoma revealed by targeted allelic imbalance analysis.

Cave-Riant F, Cuillerier B, Beau-Faller M, Martinet N, Alla F, Bronner C, Schneider A, Oudet P, Gaub MP. Cave-Riant F, et al. Am J Respir Cell Mol Biol. 2002 Oct;27(4):495-502. doi: 10.1165/rcmb.4800. Am J Respir Cell Mol Biol. 2002. PMID: 12356584

3

Genetic heterogeneity in lung and colorectal carcinoma as revealed by microsatellite analysis in plasma or tumor tissue DNA.

Beau-Faller M, Weber JC, Schneider A, Guèrin E, Gasser B, Ducrocq X, Jaeck D, Wihlm JM, Quoix E, Gaub MP. Beau-Faller M, et al. Cancer. 2003 May 1;97(9):2308-17. doi: 10.1002/cncr.11324. Cancer. 2003. PMID: 12712488 Free article.

4

Use of magnetic beads for plasma cell-free DNA extraction: toward automation of plasma DNA analysis for molecular diagnostics.

Stemmer C, Beau-Faller M, Pencreac'h E, Guerin E, Schneider A, Jaqmin D, Quoix E, Gaub MP, Oudet P. Stemmer C, et al. Clin Chem. 2003 Nov;49(11):1953-5. doi: 10.1373/clinchem.2003.020750. Clin Chem. 2003. PMID: 14578335 No abstract available.

5

MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort.

Beau-Faller M, Ruppert AM, Voegeli AC, Neuville A, Meyer N, Guerin E, Legrain M, Mennecier B, Wihlm JM, Massard G, Quoix E, Oudet P, Gaub MP. Beau-Faller M, et al. J Thorac Oncol. 2008 Apr;3(4):331-9. doi: 10.1097/JTO.0b013e318168d9d4. J Thorac Oncol. 2008. PMID: 18379349 Free article.

6

Cross-validation study for epidermal growth factor receptor and KRAS mutation detection in 74 blinded non-small cell lung carcinoma samples: a total of 5550 exons sequenced by 15 molecular French laboratories (evaluation of the EGFR mutation status for the administration of EGFR-TKIs in non-small cell lung carcinoma [ERMETIC] project--part 1).

Beau-Faller M, Degeorges A, Rolland E, Mounawar M, Antoine M, Poulot V, Mauguen A, Barbu V, Coulet F, Prétet JL, Bièche I, Blons H, Boyer JC, Buisine MP, de Fraipont F, Lizard S, Olschwang S, Saulnier P, Prunier-Mirebeau D, Richard N, Danel C, Brambilla E, Chouaid C, Zalcman G, Hainaut P, Michiels S, Cadranel J. Beau-Faller M, et al. J Thorac Oncol. 2011 Jun;6(6):1006-15. doi: 10.1097/JTO.0b013e318211dcee. J Thorac Oncol. 2011. PMID: 21532509 Free article.

7

Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3.

Borget I, Cadranel J, Pignon JP, Quoix E, Coudert B, Westeel V, Dansin E, Madelaine J, Madroszyk A, Friard S, Daniel C, Morin F, Chouaid C; ERMETIC Collaborative Group. Borget I, et al. Eur Respir J. 2012 Jan;39(1):172-9. doi: 10.1183/09031936.00201210. Epub 2011 Jun 9. Eur Respir J. 2012. PMID: 21659409 Free article.

8

Tumor cell content for selection of molecular techniques for T790M EGFR mutation detection in non-small cell lung cancer.

Prim N, Quoix E, Beau-Faller M. Prim N, et al. J Thorac Oncol. 2011 Sep;6(9):1615-6. doi: 10.1097/JTO.0b013e31822956bc. J Thorac Oncol. 2011. PMID: 21849859 Free article. No abstract available.

9

An apoptosis methylation prognostic signature for early lung cancer in the IFCT-0002 trial.

de Fraipont F, Levallet G, Creveuil C, Bergot E, Beau-Faller M, Mounawar M, Richard N, Antoine M, Rouquette I, Favrot MC, Debieuvre D, Braun D, Westeel V, Quoix E, Brambilla E, Hainaut P, Moro-Sibilot D, Morin F, Milleron B, Zalcman G; Intergroupe Francophone de Cancérologie Thoracique. de Fraipont F, et al. Clin Cancer Res. 2012 May 15;18(10):2976-86. doi: 10.1158/1078-0432.CCR-11-2797. Epub 2012 Mar 20. Clin Cancer Res. 2012. PMID: 22434665 Clinical Trial.

10

RhoB determines tumor aggressiveness in a murine EGFRL858R-induced adenocarcinoma model and is a potential prognostic biomarker for Lepidic lung cancer.

Calvayrac O, Pradines A, Raymond-Letron I, Rouquette I, Bousquet E, Lauwers-Cances V, Filleron T, Cadranel J, Beau-Faller M, Casanova A, Milia J, Favre G, Mazières J. Calvayrac O, et al. Clin Cancer Res. 2014 Dec 15;20(24):6541-50. doi: 10.1158/1078-0432.CCR-14-0506. Epub 2014 Oct 15. Clin Cancer Res. 2014. PMID: 25320360

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

61 results

Search Page

Filters